ArticleDiabetologia2008
Diabetes Antibody Standardization Program: evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen-2.
Article in Diabetologia, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 120 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
120 citing papers in PubMed, 2 syntheses or guidelines pooled it, 278 citations in OpenAlex.
- Established and emerging biomarkers for the prediction of type 1 diabetes: a systematic review.Translational research : the journal of laboratory and clinical medicine · 2014Pooled it
- Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus.Diabetes care · 2011Guideline
- Trial
- Complement gene variants in relation to autoantibodies to beta cell specific antigens and type 1 diabetes in the TEDDY Study.Scientific reports · 2016Trial
- Alloantibody and autoantibody monitoring predicts islet transplantation outcome in human type 1 diabetes.Diabetes · 2013Trial
- Evidence that nasal insulin induces immune tolerance to insulin in adults with autoimmune diabetes.Diabetes · 2011Trial
- Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy.Journal of autoimmunity · 2010Trial
- Article
- Islet autoantibodies in Thai individuals diagnosed with type 1 diabetes before 30 years of age: a large multicentre nationwide study.Diabetologia · 2025Article
- Time to reframe the disease staging system for type 1 diabetes.The lancet. Diabetes & endocrinology · 2024Review
- Utility of Fasting C-Peptide for the Diagnostic Differentiation of Patients with Type 1, Type 2 Diabetes, MODY, and LADA.Life (Basel, Switzerland) · 2024Article
- Multi-omics Investigations in Endocrine Systems and Their Clinical Implications.Advances in experimental medicine and biology · 2024Article
- Prevalence of Positivity for Diabetes-Associated Autoantibodies in Individuals with Type 2 Diabetes and Their Further Characterisation: Cross-sectional Study from Slovakia.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2023Article
- Improving diagnostic accuracy of 3 Screen ICA ELISA kit in the identification of Japanese type 1 diabetes.Journal of diabetes investigation · 2023Article
- Reclassification of type 2 diabetes to type 1 diabetes in Asturias (Spain) between 2011 and 2020.Diabetology & metabolic syndrome · 2023Article
- Bivalent GAD autoantibody ELISA improves clinical utility and risk prediction for adult autoimmune diabetes.Journal of diabetes investigation · 2023Article
- Comparing the clinical significance and antigen specificity of insulinoma-associated antigen-2 autoantibodies between radioimmunoassay and enzyme-linked immunosorbent assay in Japanese patients with type 1 diabetes.Journal of diabetes investigation · 2023Article
- The measurement of autoantibodies to insulin informs diagnosis of diabetes in a childhood population negative for other autoantibodies.Diabetic medicine : a journal of the British Diabetic Association · 2022Article
- Insulin resistance relates to DKA severity and affects insulin requirement in children with type 1 diabetes at onset.Pediatric diabetes · 2022Article
- Progression likelihood score identifies substages of presymptomatic type 1 diabetes in childhood public health screening.Diabetologia · 2022Article
60 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 3 countries.
Funding
Abstract
aims/hypothesisIslet autoantibodies are important in diabetes classification and risk assessment, and as endpoints in observational studies. The Diabetes Autoantibody Standardization Program (DASP) aims to improve and standardise measurement of autoantibodies associated with type 1 diabetes. We report results for glutamic acid decarboxylase autoantibodies (GADA) and islet antigen-2 autoantibodies (IA-2A) from three DASP workshops (2002--2005).
methodsUp to 60 laboratories in 18 countries participated in each workshop. Participants received coded serum aliquots from 50 patients with newly diagnosed type 1 diabetes (median age 18 years, range 9-35 years) and 100 blood donor controls. Results were analysed using receiver operator characteristic (ROC) curves with sensitivity adjusted to 95% specificity in workshop controls.
resultsGADA assays performed well in all three workshops (median area under the ROC curve [AUC] 0.94; interquartile range 0.91-0.95) and performance was similar to DASP 2000. Performance of IA-2A assays improved over the workshop programme. Median AUC was 0.81 (interquartile range 0.79-0.83) in DASP 2002, 0.82 (interquartile range 0.78-0.84) in 2003, and 0.85 (interquartile range 0.82-0.87) in 2005 (p < 0.0001). Performance of GADA ELISA improved between 2002 and 2005, and, in DASP 2005, achieved higher median AUC and adjusted sensitivity than RIA. IA-2A ELISA improved and, in DASP 2005, achieved AUCs equivalent to in-house RIA. Assays using IA-2ic or full length IA-2 clones were more sensitive than those using IA-2bdc, with higher AUC (p = 0.004). CONCLUSIONS/
interpretationGADA and IA-2A assays perform well in discriminating health and disease. The workshop format highlights systematic differences related to assay method and allows full evaluation of novel methods. The programme of autoantibody workshops in type 1 diabetes provides a model for other autoimmune diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.